So I think most of you on the call are familiar with MCT8 deficiency. But a quick reminder then, that MCT8 deficiency is caused by a dysfunctional thyroid hormone transporter, which is encoded on the X chromosome.
These mutations appear in approximately 1 in 70,000 boys, which translates to about 1 in 140,000 of the general population. So thyroid hormone needs to enter the cells in order to have their biological activity. And for this, they need active transporters. Importantly, MCT8 is one of several thyroid hormone transporters in the body. So when you have MCT8 deficiency, you will have an MCT8-dependent compartment.
Most importantly, the CNS and parts of the hypothalamus which regulate thyroid hormone homeostasis. Concurrently, we will have no or very low thyroid hormone level. Then we have the rest of the body and organs, which will in turn suffer too. As a result of disrupted thyroid hormone homeostasis, we see too high thyroid hormone levels circulating in the system, and with intact transporters transporting the same thyroid hormone into these organs. So, next slide, please.
So what does this mean for the patients? The chronic peripheral thyrotoxicosis results in failure to thrive. Very low body weight, decreased muscle mass, constant stress on the cardiovascular system with hypertension, arrhythmias, and also sleep disturbances. On the other hand, it is well known that too low thyroid hormone levels in the central nervous system, regardless of the cause, are linked to impaired neurocognitive development, which results in severe intellectual and motor disabilities in these patients.
Altogether, this translates into a very severe syndrome with severe and pronounced morbidity across organs and with a significantly reduced median life expectancy of 35 years. As you can understand, there is a significant unmet medical need, and currently, there are no approved treatments on the market. Next slide. And this is also the basis for the marketing authorisation application, which was submitted to the EMA last October and will likewise be the basis for the submission in the US, together with the ongoing ReTRIACt trial. However, as a reminder, in the Triac Trial II, we also had an exploratory endpoint which looked at neurocognitive development, where we saw signs of an effect in the very youngest patients below four years of age. You can see that's the left part of the graph here, where you can observe a tendency of effect with blue arrows ascending from the orange baseline values. So this finding was the basis for designing the Triac Trial II to look specifically at this part of the disease. And in this subgroup of the very youngest patients. For the study design, 22 patients younger than 30 months of age were included and followed for 96 weeks. Recruitment was completed in spring 2022 and included five sites in the Netherlands, Germany, the US, and the Czech Republic. In order to maximize the thyroid mimetic stimulation in the MCT8-dependent compartment. These patients were dosed at much higher doses per kilogram of body weight compared to previous studies. The primary endpoint in this trial was a combination of the total score in Gross Motor Function Measure (GMFM) and the gross motor scale domain of the Bayley Scales of Infant and Toddler Development III (BSID-III). It's noteworthy that assessing neurocognitive development in infants and very young children is challenging, and the available scales have been developed and validated for other conditions, such as cerebral palsy. All include a very prominent Gross Motor Function Measure component. So here, when we talk about neurocognitive development, we essentially mean gross motor function. All in all, we can conclude that the trial execution has been successful and without concerns. Next slide, please. So, coming to the gist of things, yesterday evening, as Nicholas mentioned, we issued a press release announcing the top-line results of the Triac Trial II. As already described, the Triac Trial II was designed to investigate the potential benefit on neurocognitive development in young children below 30 months of age with MCT8 deficiency. The trial included 22 patients with MCT8 deficiency treated for 96 weeks with Emcitate in higher doses per kilogram body weight as compared to the Triac Trial I. Looking at the results. While numerical improvements versus baseline were observed on the primary endpoints of neurocognitive development, these were assessed by the Gross Motor Function Measure (GMFM) scale and the Bayley Scales of Infant and Toddler Development (BSID-III). Development. The primary endpoint did not show a statistically significant improvement compared to historical controls. And by historical controls here, we mean the data that was observed in the trial. Trial one at baseline. On a more positive note, the trial did confirm the findings of previous studies with a significant and durable reduction of endogenous thyroid hormone T3 levels in all patients, which is relevant to alleviate the features of thyrotoxicosis in patients with MCT8 deficiency. Likewise, the trial confirmed the well-tolerated safety profile of Emcitate seen in previous clinical studies, despite much higher dosing per kilogram body weight compared to previous trials. At the moment, this is all we can disclose regarding the results, but the data will be presented at upcoming medical meetings and also submitted to a peer-reviewed medical journal led by the team of the principal investigator, Professor Edward Visser, at BMC Medical Center in Rotterdam, the Netherlands. So with that, I hand back to Nicklas.